The two were awarded the Nobel Prize in Chemistry, a recognition that typically takes decades to bestow, just eight years after the breakthrough. A mere three years more went by before regulators in the United States and United Kingdom approved the first CRISPR-based therapy, known as Casgevy, for use in humans.
It's a story of astonishing speed. But the continued development of CRISPR-based therapies, especially for rare diseases, could soon stall out, with treatment options delayed by years, decades, or longer – unless industry, academia, and government work together to design new scientific and regulatory models that can keep pace.
With this challenge in mind, Danaher is building a collaborative center with the Innovative Genomics Institute (IGI) – the world-class academic organization led by Doudna, which aims to use genome engineering to solve some of humanity’s greatest problems. The Danaher-IGI Beacon for CRISPR Cures seeks to use the power of CRISPR-based gene editing to permanently address hundreds of diseases with a unified scientific and technological approach – one designed to parallel-track and accelerate the development of dozens or even hundreds of therapies for diseases that might otherwise never be treated.